SAGE Therapeutics (SAGE) Tops Q4 EPS by 4c

SAGE Therapeutics (NASDAQ: SAGE) reported Q4 EPS of ($2.12), $0.04 better than the analyst estimate of ($2.16). Revenue for the quarter came in at $1.64 million versus the consensus estimate of $1.97 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• FGI Industries Ltd (FGI) Tops Q2 EPS by 59c
• Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c